BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schiefelbein E, Zekri AR, Newton DW, Soliman GA, Banerjee M, Hung ChW, Seifeldin IA, Lo AC, Soliman AS. Hepatitis C virus and other risk factors in hepatocellular carcinoma. Acta Virol 2012;56:235-40. [PMID: 23043603 DOI: 10.4149/av_2012_03_235] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Abdel-Rahman O, Abdel-Wahab M, Shaker M, Abdel-Wahab S, Elbassiony M, Ellithy M. Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma. Med Oncol 2013;30:655. [PMID: 23824645 DOI: 10.1007/s12032-013-0655-z] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 3.7] [Reference Citation Analysis]
2 Alavian SM, Haghbin H. Relative Importance of Hepatitis B and C Viruses in Hepatocellular Carcinoma in EMRO Countries and the Middle East: A Systematic Review. Hepat Mon. 2016;16:e35106. [PMID: 27226803 DOI: 10.5812/hepatmon.35106] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 4.8] [Reference Citation Analysis]
3 Abdel-Rahman O, Elsayed Z. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2020;1:CD011313. [PMID: 31978267 DOI: 10.1002/14651858.CD011313.pub3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 AlZoubi AM, Khalifeh F. The effectiveness of stem cell therapies on health-related quality of life and life expectancy in comparison with conventional supportive medical treatment in patients suffering from end-stage liver disease. Stem Cell Res Ther 2013;4:16. [PMID: 23510679 DOI: 10.1186/scrt164] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
5 Fouad M, Abdel-Rahman O. Combination of transarterial chemoembolisation (TACE) plus antivirals for the management of hepatitis B-related hepatocellular carcinoma: A systematic review of the literature. Arab J Gastroenterol 2015;16:40-5. [PMID: 25910573 DOI: 10.1016/j.ajg.2015.03.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
6 Abdel-rahman O, Elsayed ZA. Combination Trans Arterial Chemoembolization (TACE) Plus Sorafenib for the Management of Unresectable Hepatocellular Carcinoma: A Systematic Review of the Literature. Dig Dis Sci 2013;58:3389-96. [DOI: 10.1007/s10620-013-2872-x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 5.6] [Reference Citation Analysis]
7 VoPham T, Bertrand KA, Hart JE, Laden F, Brooks MM, Yuan JM, Talbott EO, Ruddell D, Chang CH, Weissfeld JL. Pesticide exposure and liver cancer: a review. Cancer Causes Control 2017;28:177-90. [PMID: 28194594 DOI: 10.1007/s10552-017-0854-6] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 7.2] [Reference Citation Analysis]
8 Abdel-Rahman OM, Elsayed Z. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2016;2:CD011313. [PMID: 26905230 DOI: 10.1002/14651858.CD011313.pub2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
9 Abdel-rahman O, Abdelwahab M, Shaker M, Abdelwahab S, Elbassiony M, Ellithy M. Sorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience. Journal of the Egyptian National Cancer Institute 2014;26:9-13. [DOI: 10.1016/j.jnci.2013.08.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]